Health News
FDA Approves Perjeta for Neoadjuvant Breast Cancer Treatment
The US Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting).
FDA Expands Use of Breast Cancer Rx
For the first time in its history, the US Food and Drug Administration has approved a medication for the pre-surgical (neoadjuvant) treatment of early-stage (I, II) breast cancer.